BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company o... BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates through a distinctive decentralized hub-and-spoke model, where autonomous teams focus on individual disease conditions while a central hub provides shared clinical, regulatory, and commercial expertise. BridgeBio's commercial-stage pipeline includes Attruby (acoramidis), an oral small molecule transthyretin stabilizer for transthyretin-mediated amyloidosis cardiomyopathy, alongside late-stage programs for conditions including limb girdle muscular dystrophy, autosomal dominant hypocalcemia, achondroplasia, and Canavan disease. The company partners with leading academic institutions to advance early-stage research and accelerate the development of first-in-class treatments for underserved patient populations lacking adequate therapeutic options. BridgeBio's focused approach on genetic diseases with clear genetic drivers enables precision targeting at the disease source, positioning the company as a leader in precision medicine for rare genetic conditions.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

BridgeBio Pharma is not subject to EU Taxonomy reporting

Based on current regulatory requirements, BridgeBio Pharma is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review BridgeBio Pharma's data?

Start your 30-day free trial to request a data review for BridgeBio Pharma.

Start Free Trial

Legal Center Contact Us

BridgeBio Pharma Inc

BridgeBio Pharma is not subject to EU Taxonomy reporting

Account Restricted